Nasdaq · Common stock
Attovia Therapeutics (ATTO)
$13.88 +$0.05 (+0.36%)
- Day’s range
- $13.62–$14.48
- Volume
- 224,636
ATTO price history
ATTO closed at $13.88 on Oct. 26, 2026. Over the past year, its daily close ranged from $13.73 on Oct. 16, 2026 to $25.55 on Sept. 4, 2026.
Data table: ATTO daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $13.88 |
| Oct. 23, 2026 | $13.83 |
| Oct. 22, 2026 | $14.50 |
| Oct. 21, 2026 | $14.18 |
| Oct. 20, 2026 | $14.04 |
| Oct. 19, 2026 | $13.89 |
| Oct. 16, 2026 | $13.73 |
| Oct. 15, 2026 | $14.78 |
| Oct. 14, 2026 | $14.96 |
| Oct. 13, 2026 | $14.72 |
| Oct. 12, 2026 | $14.59 |
| Oct. 9, 2026 | $16.21 |
| Oct. 8, 2026 | $16.31 |
| Oct. 7, 2026 | $16.42 |
| Oct. 6, 2026 | $17.50 |
| Oct. 5, 2026 | $18.00 |
| Oct. 2, 2026 | $17.17 |
| Oct. 1, 2026 | $17.79 |
| Sept. 30, 2026 | $17.14 |
| Sept. 29, 2026 | $18.16 |
| Sept. 28, 2026 | $17.65 |
| Sept. 25, 2026 | $17.78 |
| Sept. 24, 2026 | $18.17 |
| Sept. 23, 2026 | $18.52 |
| Sept. 22, 2026 | $20.83 |
| Sept. 21, 2026 | $21.30 |
| Sept. 18, 2026 | $22.14 |
| Sept. 17, 2026 | $22.73 |
| Sept. 16, 2026 | $22.25 |
| Sept. 15, 2026 | $23.70 |
| Sept. 14, 2026 | $24.52 |
| Sept. 11, 2026 | $22.79 |
| Sept. 10, 2026 | $22.53 |
| Sept. 9, 2026 | $22.86 |
| Sept. 8, 2026 | $23.66 |
| Sept. 4, 2026 | $25.55 |
| Sept. 3, 2026 | $24.20 |
| Sept. 2, 2026 | $23.13 |
| Sept. 1, 2026 | $22.22 |
| Aug. 31, 2026 | $21.40 |
| Aug. 28, 2026 | $20.70 |
| Aug. 27, 2026 | $21.46 |
| Aug. 26, 2026 | $19.55 |
| Aug. 25, 2026 | $19.31 |
| Aug. 24, 2026 | $20.62 |
| Aug. 21, 2026 | $20.80 |
| Aug. 20, 2026 | $20.21 |
| Aug. 19, 2026 | $22.14 |
| Aug. 18, 2026 | $23.24 |
| Aug. 17, 2026 | $22.71 |
| Aug. 14, 2026 | $19.86 |
| Aug. 13, 2026 | $19.18 |
| Aug. 12, 2026 | $18.06 |
| Aug. 11, 2026 | $18.65 |
| Aug. 10, 2026 | $19.84 |
| Aug. 7, 2026 | $20.17 |
| Aug. 6, 2026 | $20.38 |
| Aug. 5, 2026 | $21.90 |
Key figures
- Average daily volume
- 441,883Past 3 months
- Market value
- $633.6M
- Dividend yield
- —
Price change
- 1 month
- −21.93%
What Wall Street says about ATTO
In the past 90 days, Wall Street firms published 5 rating or price-target actions on ATTO: 5 new ratings.
| Action | Rating | |||
|---|---|---|---|---|
| Citigroup | Initiates coverage | Buy | $30 | |
| Leerink Partners | Initiates coverage | Outperform | $52 | |
| LifeSci Capital | Initiates coverage | Outperform | $45 | |
| Morgan Stanley | Initiates coverage | Overweight | $39 | |
| RBC Capital | Initiates coverage | Outperform | $45 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
- Headquarters
- San Carlos, Calif.
- Listed
- Aug. 5, 2026
- Sector
- Health care
- Industry
- Biological products, (no diagnostic substances)
In WallStreetDigest editions
No WallStreetDigest article about ATTO is on the site yet.